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Effect of alpha- and beta-adrenergic stimulation on renal water
excretion in man. Intravenously administered isoproterenol
(ISO) (0.04—0.06 g/kg/min) was infused into four normal sub-
jects and four patients with pituitary diabetes insipidus (DI) who
were undergoing water diuresis. Each normal subject demon-
strated an antidiuresis as mean urinary osmolality (Uosm) in-
creased from 75 5 to 324 84 mOsm (F <0.05) and decreased
to 90±10 mOsm (P< 0.05) after ISO administration. In contrast,
the DI subjects did not demonstrate an antidiuresis as Uosm was
90± 13, 79±16 and 94±16 mOsm before, during and after i.v.
administration of ISO. The effect of alpha-adrenergic stimulation
with i.v. administration of norepinephrine (NE) (600 g/hr) was
also examined in four hydropenic normal subjects and four DI
subjects receiving 10 to 20 mU of vasopressin/hr. In the normal
subjects i.v. administration of NE was associated with a decrease
in Uosm from 437±61 to 128± 17 mOsm (P<0.001) which in-
creased to 441 26 mOsm (P <0.001) after i.v. administration of
NE. In contrast, no diuresis occurred in the DI patients as Uosm
was 493 77, 535 61 and 541 69 mOsm before, during and
after iv. administration of NE. The systemic and renal hemo-
dynamic effects of ISO and NE were comparable in the normal
and DI subjects. The present results therefore indicate that in
man alpha- and beta-adrenergic stimulation with i.v. adminis-
tered NE and ISO affects renal water excretion primarily by
altering the release of endogenous vasopressin.
L'effet de Ia stimulation alpha et beta adrenergique sur
I'excrétion rénale d'eau chez l'homme. Une perfusion intra-
veineuse (IV) d'isoprotérènol (ISO) (0,04—0,06 g/kg/min) a été
administrée a quatre subjets normaux et a quatre malades atteints
de diabète insipide hypophysaire (DI) soumis a une diurèse
aqueuse. Une situation d'antidiurêse est apparuechez chacun
des sujets normaux traduite par une élévation de l'osmolalité
urinaire moyenne de 75 5 a 324 84 mOsm (P <0,05) et une
diminution a 90±10 mOsm (P<0,05) après l'arrêtde l'isopro-
térénol. Les sujets atteints de DI, au contraire, n'ont pas été en
situation d'antidiurèse car Uosmétait de9O 13,79 11 et 94 16
mOsm avant, pendant et après la perfusion. L'effet de la stimu-
lation par Ia norépinéphrine (NE) IV (600 g/heure) a aussi été
étudié chez quatre sujets normaux hydropeniques et quatre DI
qui recevaient 10 a 20 mU de vasopressine par heure. Chez les
sujets normaux NE a été associé a une diminution de Uosm de
437 61 a 128 17 mOsm (P< 0,001). Après la perfusion Uosm a
atteint 441 26 mOsm (P< 0,001). Chez les DI, au contraire,
aucune modification de Ia situation de diurése n'est apparue
puisque Uosm était de 493 77, 535 61 et 541 69 mOsm avant,
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pendant et aprés NE intraveineuse. Les effets systémiques et
hémodynamiques rénaux de l'ISO et de NE intraveineuse ont été
comparables chez les sujets normaux et les DI. Ces résultats
indiquent donc que, chez l'homme, la stimulation alpha et betz
adrénergique par NE et ISO intraveineuse affectent l'excrétion
rénale d'eau en altérant la liberation de Ia vasopressine endogene.
Investigations both in man [1—4] and in experi-
mental animals [5—8] have shown that the infusion of
catecholamines profoundly alters renal water excre-
tion. Recent studies in the anesthetized dog suggest
that these changes in water excretion are mediated
primarily by alterations in the release of endogenous
vasopressin rather than by changes in renal hemo-
dynamics or a direct intrarenal effect of the catecho-
lamines on the water permeability of the renal tubule
[9, 10]. In this regard, in the dog, beta-adrenergic
stimulation produces antidiuresis primarily by increas-
ing vasopressin release while alpha-adrenergic stimula-
tion causes diuresis by suppressing the release of en-
dogenous antidiuretic hormone.
The study of Fisher [3], however, casts some doubt
on whether these same mechanisms are operative in
man. In his study, i.v. administration of norephine-
phrine caused diuresis in water-loaded subjects receiv-
ing small, but not large, doses of vasopressin. These
results were interpreted to support a competitive in-
hibition of the hydroosmotic effect of vasopressin by
norepinephrine at the level of the renal tubule rather
than any effect involving a suppression of endogenous
vasopressin release. Such an interpretation indeed is
compatible with some in vitro results in the toad
bladder [11, 12] and frog skin [13] but is not compatible
with recent in vivo results in the dog [9, 10]. The me-
chanism whereby beta-adrenergic stimulation with
isoproterenol causes antidiuresis in man is also not
clear. The results of in vitro studies performed in dog
medullary tissue suggest the possibility of a 3', 5'-
adenosine monophosphate (cyclic AMP)-mediated
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intrarenal mechanism [14], while the recent in vivo dog
studies suggest an effect involving an increase in vaso-
pressin release [9].
The present investigation, therefore, was under-
taken to examine the effects of both alpha- and beta-
adrenergic stimulation on water excretion in man and
to define the mechanism of such effects. The results of
these studies demonstrate that an infusion of isopro-
terenol causes antidiuresis in normal subjects but not in
patients with pituitary diabetes insipidus. Likewise,
i.v. administration of norepinephrine cause diuresis in
normal subjects but not in patients with diabetes in-
sipidus receiving small doses of exogenous vasopressin.
We conclude, therefore, that in man the major effect of
catecholamines on renal water excretion is mediated
by changes in endogenous vasopressin release.
Methods
Studies were performed on eight healthy volunteers,
four of whom were given isoproterenol and four of
whom received norepinephrine. Four patients with
pituitary diabetes insipidus were studied on two
separate occasions while receiving either isoproterenol
or norepinephrine. All subjects were fasted and not
allowed to smoke after midnight of the day of the study.
The studies were performed at the Clinical Research
Center of the University of Colorado Medical Center.
Patients suffering from pituitary diabetes insipidus
were requested not to take their pitressin medication
for 36 hr prior to study. Two of these patients had been
found previously not to respond to chlorpropamide
therapy. The studies were started at approximately
8:00 AM by commencing a sustaining infusion of
inulin and para-aminohippurate (PAH) in normal
saline solution at 1.0 mI/mm. Throughout the experi-
ment, the subjects remained recumbent except while
voiding. Urine was collected at 30- to 60-mm intervals.
Venous blood was obtained in each phase of the study
for measurement of inulin, PAH, sodium and osmol-
ality. Blood pressure and pulse rate were recorded
every 15 to 30 mm throughout the study. The follow-
ing group of experiments was performed.
Intravenous administration of isoproterenol to normal
subjects undergoing water diuresis and patients with
diabetes insipidus. In order to achieve water diuresis,
the four normal subjects received an orally admini-
stered water load of 20 mI/kg from 8:00 to 8:30 AM on
the morning of the study. Urinary losses were replaced
with orally administered fluids in both the normal sub-
jects and the patients with pituitary diabetes insipidus.
The experiments were started in both groups when
urine flow stabilized. After three control periods, iso-
proterenol (0.04 to 0.06 g/kg/min at 0.5 ml/min) was
infused with a pump (Sigmamotor). After a 30-mm
equilibration period, two or three experimental urin-
ary collections were obtained and the infusion was
then discontinued. After another 30-mm equilibration
period, two or three postcontrol collections were
obtained.











Pre iso PostPre Iso Post Pre Iso Post
control control control control control control
Normal
1 M 33 70 84 65 80 65 118 72 98 138 131
2 F 23 50 89 77 88 59 119 60 77 76 87
3 M 38 91 90 72 88 59 120 76 117 117 138
4 M 34 67 98 75 88 77 118 89 119 136 134
Mean 90 72 86 65 118 72 102 116 122
SEM ±3 ±3 ±2 ±4 ±1 ±7 ±4.0 ±14.0 ±12.0
P <0.001 <0.001 <0.001 <0.001 NS NS
Patients with
5 M 20 76 93 82 93 58 108 56 110 103 99
6 F 27 95 110 95 108 93 128 96 139 140 149
7 M 21 65 83 71 78 72 122 76 75 65 66
8 M 19 68 73 63 80 60 96 64 110 109 129
Mean 90 78 90 71 114 73 108 104 111
SEM ±8 ±7 ±7 ±8 ±7 ±9 ±12 ±15 ±19
p <0.005 <0.005 <0.001 <0.001 NS NS
GFR =glomerular filtration rate; CPAH = clearance rate of para-aminohippurate.
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Intravenous administration of norepinephrine in nor-
mal subjects and in patients with diabetes insipidus. The
patients with diabetes insipidus received an infusion of
vasopressin (Aqueous Pitressin U.S.P., Parke Davis)
in a dose of 10 to 20 mU/hr at 0.5 mI/mm which was
started at 8:00 AM and continued throughout the
study. To avoid excessively high control urinary
osmolalities, the normal subjects were allowed to
drink small amounts of fluid ad lib. In both the normal
subjects and patients suffering from diabetes insipidus,
the experiments were started after urine flows had
stabilized. Three control urine collections were ob-
tained and then an infusion of norepinephrine (10 to
15 g/min at 0.5 mI/mm) was begun. After an equili-
bration period of 30 mm, two or three experimental
urine collections were obtained and the norepine-
phrine infusion was discontinued. Another comparable
equilibration period then was obtained after which two
or three postcontrol urine collections were made. The
analytical procedures used in the present experiments
have been referred to elsewhere [15]. A two-way
analysis of variance was used to analyze differences
between control, experimental and postcontrol meas-
urements. A P value less than 0.05 was considered
significant.
Results
Intravenous administration of isoproterenol in normal
subjects undergoing water diuresis and patients with
diabetes insipidus (Table 1). The infusion of the beta-
adrenergic agonist, isoproterenol, caused palpitations
and flushing in all subjects. The changes in systemic
hemodynamics were similar in the normal subjects and
patients with diabetes insipidus as mean arterial pres-
sure decreased and pulse rate increased in all subjects.
Neither reversible nor statistically significant effects on
glomerular filtration rate (GFR), clearance of PAH or
solute excretion were observed in either group of
patients. In contrast, the changes in renal water excre-
tion were markedly different in the two groups. All
four normal subjects had an increase in urinary osmol-
ality (Uosm) and a decrease in free water clearance
(C1120) during the infusion of isoproterenol, while no
changes in renal water excretion were observed in the
subjects with diabetes insipidus (Fig. 1).
Intravenous administration of norepinephrine in nor-
ma! subjects and patients with diabetes insipidus
(Table 2). Infusion of the submaximal dose of vaso-
pressin increased the Uosm of the patients with dia-
betes insipidus to a mean of 493±77 mOsm/kg. Infu-
sion of norepinephrine was tolerated well by all sub-
jects. An increase in mean arterial systemic pressure
was observed in all instances. Similarly, the pulse rate
decreased in all subjects, but the decrease did not attain
statistical significance in the patients with diabetes in-
sipidus. There were no significant changes in GFR in
either the normal subjects or patients with diabetes
insipidus during infusion of norepinephrine. Although
the clearance of PAH decreased in all subjects during









Pre Iso Post Pre Iso Post Pre Iso Post Pre Iso Post
control control control control control control control control
controls
615 845 883 3.42 1.06 2.52 11.25 —0.115 5.00 65 324 105
396 403 479 2.36 2.06 2.18 7.64 0.194 7.97 67 259 61
485 524 711 4.41 2.59 3.10 10.90 —0.80 6.00 82 557 104
648 775 773 3.14 2.48 2.59 12.1 2.03 5.66 87 158 90
536 636 711 3.33 2.04 2.59 10.4 0.317 6.25 75 325 90
+58 +104 +85 +0.42 +0.34 +0.19 +0.97 +0.60 +0.58 +5 +85 +10
NS NS <0.05 NS <0.001 <0.01 <0.05 <0.05
diabetes insipidus
526 493 489 3.00 2.15 1.87 4.63 4.11 2.13 110 86 113
655 706 719 2.61 2.38 2.18 8.92 9.43 6.67 66 60 72
409 342 344 3.16 3.01 3.11 5.03 5.25 5.39 116 107 109
714 757 745 3.21 3.20 3.33 10.1 11.2 11.1 67 62 62
576 565 524 3.00 2.69 2.62 7.17 7.50 6.31 90 79 94
±136 ±193 ±192 ±0.14 ±0.25 ±0.35 ±1.4 ±1.7 ±1.8 ±13 ±11 ±16
NS NS NS NS NS NS NS NS
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administration of norepinephrine, these changes were
not statistically significant. A decrease in solute clear-
ance occurred in patients with diabetes insipidus, but
the effect was not reversible. The effect of norepine-
phrine on water excretion, however, was strikingly 500
different in the two groups (Fig. 2). Norepinephrine
caused reversible diuresis in normal subjects as CH2O 400
increased and Uosm decreased. In contrast, the
patients with diabetes insipidus, in spite of starting 300
with comparable urinary osmolalities, showed no
change in water excretion as neither Uosm nor CHZO
was significantly altered by norepinephrine infusion. 200
100
Discussion
The results of the present study support the conclu-
sion that the increase in renal water excretion observed
in normal man during the i.v. infusion of norepine-
phrine [1—3] is mediated by suppression of the endo-
genous release of vasopressin. This conclusion is
different from that of a previous study in man [3]. In
the previous study, normal volunteers received a water
load to suppress endogenous vasopressin release, and
then an exogenous infusion of vasopressin was ad-
ministered throughout the remainder of the study.
After obtaining a hypertonic urine with the exogenous
vasopressin infusion, norepinephrine was admini-
stered i.v. The same dose of i.v. administered norepine-
phrine as used in the present study was found to in-
crease free-water clearance during the infusion of 10 to
Table 2. Effect of i.v. administered norepinephrine on systemic hemodynamics, renal hemodynamics, solute
Sub-
ject






Pre Norepi Post Pre Norepi Post Pre Norepi Post
control control control control control control
Normal
9 F 27 49 83 93 78 76 70 82 119 126 159
10 M 23 77 97 108 85 56 44 68 86 92 89
11 F 23 59 83 100 83 68 52 64 101 101 92
12 F 27 59 80 97 70 84 70 88 102 97 71
Mean 86 100 79 71 59 76 102 104 103
SEM ±4 ±3 ±3 ±6 ±7 ±6 ±7 ±8 ±19P <0.005 <0.001 <0.025 <0.005 NS NS
Patients with
5 M 20 76 90 115 97 68 55 74 77 101 110
6 F 27 95 105 121 110 92 79 114 124 94 122
7 M 21 65 78 99 77 64 58 72 64 82 69
8 M 19 68 73 97 83 64 52 60 140 130 151
Mean 87 108 92 72 61 80 10! 102 113
SEM ±7 ±6 ±7 ±7 ±6 ±11 ±18 ±10 ±17p <0.001 <0.005 NS <0.025 NS NS
Fig. 1. Antidiuretic effect of i.v. administered isoproterenol in nor-
mal subjects (solid lines) but not in patients with pituitary
diabetes ins ipidus (broken lines).







Fig. 2. Diuretic effect of i.v. administered norepinephrine in nor-
mal subjects (solid lines) but not in patients with pituitary diabetes
insipidus (broken lines).
20 mU/hr, but not 50 or 100 mU/hr, of exogenous
vasopressin. A mechanism involving competitive in-
hibition between vasopressin and norepinephrine was
suggested to explain this capacity of norepinephrine to
reverse the antjdiuretic effect of modest doses of vaso-
pressin. In this regard, recent in vitro studies in dog [14]
and rat renal medulla [16] have demonstrated that
norepinephrine diminishes the effect of vasopressin to
generate cyclic AMP. Norepinephrine has also been
shown to inhibit the hydroosmotic effect of vasopres-
sin in toad bladder [11, 12] and frog skin [13].
In contrast, recent studies performed in our labor-
atory in the dog indicate that norepinephrine induces
diuresis by suppressing the release of endogenous
vasopressin. Rather than invoking a species difference
between man and dog, the possibility was entertained
that in the earlier studies in man [3] endogenous vaso-
pressin was not maximally suppressed during the ad-
ministration of norepinephrine. Although minimal
urinary osmolalities in this previous study were in the
range of 40 to 80 mOsm/kg immediately after the
water load, there is no means to substantiate that one
to two hours later when the norepinephrine was in-
fused, substantial amounts of endogenous vasopressin
were not present. Such a possibility is quite compatible
with the observation that norepinephrine induced
diuresis only in the presence of submaximal doses of
exogenous vasopressin, a state in which changes in
endogenous vasopressin would be expected to alter
urine flow. Unfortunately, cessation of the vasopressin









Pre Norepi Post Pre Norepi Post Pre Norepi Post Pre Norepi Post
control control control control control control control control
controls
583 488 825 2.63 2.14 2.80 —1.15 +1.61 —0.91 517 166 441
508 423 480 2.07 2.08 1.71 —0.94 +2.9 —0.64 552 124 499
569 472 534 3.90 3.27 2.27 —1.00 +3.98 —0.10 393 137 449
330 283 221 3.21 2.52 1.38 —0.01 +6.11 —0.34 286 85 373
485 417 515 2.95 2.50 2.00 —0.77 + 3.65 —0.50 437 128 441
±53 ±46 ±123 ±0.39 ±0.27 ±0.31 ±0.26 ±0.95 ±0.18 ±61 ±17 ±26
NS NS NS NS <0.005 <0.005 <0.001 <0.001
diabetes insipidus
573 395 497 2.93 2.17 2.01 —0.30 —0.61 —0.56 326 395 410
674 345 638 1.98 1.50 1.56 —1.17 —0.87 —0.93 692 692 733
372 329 428 2.38 2.09 2.18 —0.71 —0.91 —0.94 434 532 528
736 684 812 3.70 2.80 2.60 —1.71 —1.35 —1.20 518 522 493
589 438 594 2.75 2.14 2.09 —0.97 —0.93 —0.91 493 535 541
±80 ±83 ±85 ±0.37 ±0.26 ±0.21 ±0.30 ±0.15 ±0.13 ±77 ±61 ±69
NS NS <0.025 NS NS NS NS NS
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infusion at the end of the experiments and demonstra-
tion of a persistent minimal Uosm was not reported
[3]. Such postcontrol observations would have pro-
vided support that changes in urine flow during the
norepinephrine infusion were not due to alterations in
endogenous vasopressin.
In an effort to more conclusively exclude a role of
endogenous vasopressin in the present investigation,
the effect of alpha-adrenergic stimulation with nore-
pinephrine on renal water excretion was examined in
normal subjects and in patients suffering from diabetes
insipidus. If norepinephrine is, indeed, a competitive
inhibitor of vasopressin in man [3], it should cause
water diuresis in both normal hydropenic man and
patients with pituitary diabetes insipidus who are re-
ceiving the same submaximal dose of exogenous vaso-
pressin as previously used by Fisher [3]. In the present
study the mean urinary osmolalities in the normal sub-
jects (437 mOsm) and the patients suffering from dia-
betes insipidus but receiving exogenous vasopressin
(493 mOsm) were comparable prior to the infusion of
norepinephrine. Even so, the infusion of norepine-
phrine caused a water diuresis only in the normal sub-
jects. It should be pointed out that the Uosm (314
mOsm) in the previous study in water-loaded subjects
receiving 10 to 20 mU/hr of vasopressin [3] was some-
what less than the mean Uosm (493 mOsm) in our
subjects with diabetes insipidus receiving the same dose
of vasopressin. This difference does not, however,
seem to offer an adequate explanation for the different
effects of norepinephrine on water excretion since the
control urinary osmolalities in three of our patients
with diabetes insipidus (326, 434 and 518 mOsm) were
well within the range of control urine osmolalities
(100 to 667 mOsm) in these previous water-loaded sub-
jects receiving vasopressin [3]. The control Uosm
(692 mOsm) of our fourth patient was also not far out-
side of this range. Taken together, the present results
would thus seem to clearly implicate a role of suppres-
sion of endogenous vasopressin in the diuretic effect of
norepinephrine. In this regard, the diuretic effect of
norepinephrine in the previous study in water-loaded
subjects [3] would thus seem most likely to also have
been due to suppression of endogenous vasopressin.
The time course of the diuretic response to norepine-
phrine in this previous study and the present study in
normal subjects was quite compatible with suppression
of endogenous vasopressin. Any in vivo antagonism
between vasopressin and norepinephrine, thus, re-
mains to be demonstrated and, if present, must be
relatively minor as compared to the effect of pressor
doses of norepinephrine to suppress endogenous vaso-
pressin.
The absence of pressor doses of norepinephrine to
cause diuresis in the patients with diabetes insipidus
suggests that increases in renal perfusion pressure
(mean+21 mm Hg) may not consistently alter renal
water excretion in humans with normal renal function.
This finding is in contrast to the diuresis observed in
patients with hepatorenal syndrome during infusion of
pressor doses of the alpha-adrenergic agonist, meta-
raminol [17]. However, these patients with hepatorenal
syndrome, as well as patients with essential hyperten-
sion who demonstrate "pressure diuresis" [18], have
higher control levels of renal vascular resistance than
either our normal subjects or patients with diabetes
insipidus. These findings therefore suggest that the
baseline level of renal vascular resistance, and, thus,
perhaps vascular reactivity, is important in the pheno-
menon of "pressure diuresis".
Experiments were also performed in the present in-
vestigation to better delineate the mechanism whereby
beta-adrenergic stimulation with i .v. administered iso-
proterenol causes antidiuresis in normal subjects.
Although a recent preliminary communication in man
suggests that beta-adrenergic stimulation with isopro-
terenol causes antidiuresis by stimulating vasopressin
release [4], results from the same laboratory using a
similar bioassay method for vasopressin failed to im-
plicate vasopressin release in the antidiuretic effect of
isoproterenol infusion in the dog [6]. Also, earlier in
vitro studies in dog renal medulla suggest that an in-
crease in medullary cyclic AMP may provide an intra-
renal pathway for such an effect of isoproterenol on
renal water excretion [14].
The present results are most compatible with the
interpretation that the antidiuretic effect of beta-
adrenergic stimulation with isoproterenol is dependent
on the increased release of vasopressin. This conclusion
is supported by the finding that the antidiuretic effect
of isoproterenol is readily demonstrable in normal
subjects, but not in patients suffering from pituitary
diabetes insipidus. As in the norepinephrine studies,
these results in man are quite consistent with previous
findings in the dog [9].
Results of the present and previous studies [9, 10],
thus, seem to indicate that in both man and dog the
primary effect of alpha- and beta-adrenergic stimula-
tion to affect renal water excretion is mediated by
changes in endogenous vasopressin release. No evi-
dence in the present or previous studies [9, 10] was
found to support a direct intrarenal effect of isopro-
terenol or norepinephrine to alter renal water excretion
by a cellular interaction with vasopressin. In the
patients suffering from diabetes insipidus and receiving
modest doses of vasopressin, an additional effect of
norepinephrine to inhibit the renal tubular effect of
vasopressin should have been readily demonstrable.
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An effect of beta-adrenergic stimulation to enhance
the tubular action of vasopressin also seems unlikely.
Two of the patients with diabetes insipidus had control
urinary osmolalities (110 and 116 mOsm) which sug-
gested the presence of some vasopressin, and, yet, no
effect of isoproterenol on water excretion was ob-
served. Moreover, previous studies have been per-
formed in dogs with baroreceptor denervation in
which some residual vasopressin was likely present [19].
In these studies beta-adrenergic stimulation with iso-
proterenol did not produce antidiuresis, thus providing
no support for an enhancement of the effect of vaso-
pressin. The results of these earlier studies, however,
did indicate that alterations in parasympathetic
afferent tone are responsible for mediating the effect of
beta-adrenergic stimulation to increase vasopressin
release [19]. Similar pathways also have been demon-
strated to be involved in the effect of alpha-adrenergic
stimulation to suppress vasopressin release in the dog
[20]. It thus seems reasonable to suggest that these
baroreceptor pathways are also involved in the effects
of beta- and alpha-adrenergic stimulation to alter
vasopressin release in man.
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